The DOI matches its Crossref record; 284 of the 284 references it cites were found in a registry or an index.
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Open accessAbstract
Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to its success for hematological malignancies in clinical studies leading to the US Food and Drug Administration (FDA) approval of three CD19-targeted CAR T cell products. In contrast, the clinical experience with CAR T cell therapy for solid tumors and brain tumors has been less encouraging, with only a few patients achieving complete responses. Clinical and preclinical studies have identified multiple "roadblocks," including (1) a limited array of targetable antigens and heterogeneous antigen expression, (2) limited T cell fitness and survival before reaching tumor sites, (3) an inability of T cells to efficiently traffic to tumor sites and penetrate physical barriers, and (4) an immunosuppressive tumor microenvironment. Herein, we review these challenges and discuss strategies that investigators have taken to improve the effector function of CAR T cells for the adoptive immunotherapy of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–284 of 284
Priceman, S. J., Gerdts, E. A., Tilakawardane, D., Kennewick, K. T., Murad, J. P., Park, A. K., Jeang, B., Yamaguchi, Y., Yang, X., Urak, R., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1380764 · Cited by 166
Signal Integration by Akt Regulates CD8 T Cell Effector and Memory Differentiation
Kim, E. H., Sullivan, J. A., Plisch, E. H., Tejera, M. M., Jatzek, A., Choi, K. Y., & Suresh, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103568 · Cited by 164
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma
Quintarelli, C., Orlando, D., Boffa, I., Guercio, M., Polito, V. A., Petretto, A., Lavarello, C., Sinibaldi, M., Weber, G., Del Bufalo, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433518 · Cited by 163
Sakemura, R., Terakura, S., Watanabe, K., Julamanee, J., Takagi, E., Miyao, K., Koyama, D., Goto, T., Hanajiri, R., Nishida, T., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0043 · Cited by 161
Suppression of Tcf1 by Inflammatory Cytokines Facilitates Effector CD8 T Cell Differentiation
Danilo, M., Chennupati, V., da Silva, J. G., Siegert, S., & Held, W. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.072 · Cited by 158
Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells
Xiong, W., Chen, Y., Kang, X., Chen, Z., Zheng, P., Hsu, Y.-H., Jang, J. H., Qin, L., Liu, H., Dotti, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.020 · Cited by 157
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Yamamoto, T. N., Lee, P.-H., Vodnala, S. K., Gurusamy, D., Kishton, R. J., Yu, Z., Eidizadeh, A., Eil, R., Fioravanti, J., Gattinoni, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121491 · Cited by 156
Reactive Oxygen Species Differentially Affect T Cell Receptor-signaling Pathways*
Čemerski, S., Cantagrel, A. G., van Meerwijk, J. P. M., & Romagnoli, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111451200 · Cited by 156
Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
Huang, J., Yu, J., Tu, L., Huang, N., Li, H., & Luo, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00506 · Cited by 156
You, F., Jiang, L., Zhang, B., Lu, Q., Zhou, Q., Liao, X., Wu, H., Du, K., Zhu, Y., Meng, H., et al. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5024-7 · Cited by 155
Blaeschke, F., Stenger, D., Kaeuferle, T., Willier, S., Lotfi, R., Kaiser, A. D., Assenmacher, M., Döring, M., Feucht, J., & Feuchtinger, T. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2155-7 · Cited by 155
Hombach, A. A., & Abken, H. (2011) · International Journal of Cancer · doi:10.1002/ijc.25960 · Cited by 152
Liu, Y., Di, S., Shi, B., Zhang, H., Wang, Y., Wu, X., Luo, H., Wang, H., Li, Z., & Jiang, H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800033 · Cited by 150
Attianese, G. M. P. G., Gaínza, P., Gray-Gaillard, E. F., Cribioli, E., Shui, S., Kim, S., Kwak, M., Vollers, S. S., Osorio, A. D. J. C., Reichenbach, P., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0403-9 · Cited by 149
Cole, C., Qiao, J., Kottke, T. J., Díaz, R. M., Ahmed, A. U., Sanchez-Perez, L. A., Brunn, G. J., Thompson, J., Chester, J. D., & Vile, R. G. (2005) · Nature Medicine · doi:10.1038/nm1297 · Cited by 148
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W. G., Locke, F. L., Lin, Y., Jain, N., Daver, N. G., Gulbis, A. M., Adkins, S., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.20 · Cited by 148
Porter, C. E., Shaw, A. R., Jung, Y., Yip, T., Castro, P. D., Sandulache, V. C., Sikora, A. G., Gottschalk, S. M., Ittman, M. M., Brenner, M. K., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.02.016 · Cited by 148
Self-citationRetroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy
Griffioen, M., van Egmond, E. H. M., Kester, M. G. D., Willemze, R., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2009) · Haematologica · doi:10.3324/haematol.2008.001677 · Cited by 140
Singh, H., Huls, H. M., Kebriaei, P., & Cooper, L. J. N. (2013) · Immunological Reviews · doi:10.1111/imr.12137 · Cited by 139
Marcucci, K. T., Jadlowsky, J. K., Hwang, W., Suhoski, M. M., Gonzalez, V. E., Kulikovskaya, I. M., Gupta, M., Lacey, S. F., Plesa, G., Chew, A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.012 · Cited by 138
mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting
Lohmueller, J. J., Ham, J. D., Kvorjak, M., & Finn, O. J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1368604 · Cited by 137
Mottini, C., Napolitano, F., Li, Z., Gao, X., & Cardone, L. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.023 · Cited by 133
Nobles, C. L., Sherrill-Mix, S., Everett, J. K., Reddy, S., Fraietta, J. A., Porter, D. L., Frey, N., Gill, S. I., Grupp, S. A., Maude, S. L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci130144 · Cited by 130
Engineering switchable and programmable universal CARs for CAR T therapy
Liu, D., Zhao, J., & Song, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0763-0 · Cited by 129
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis
Dotti, G., Savoldo, B., Pulè, M. A., Straathof, K. C. M., Biagi, E., Yvon, E. S., Vigouroux, S., Brenner, M. K., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-08-3337 · Cited by 128
Modulation of chimeric antigen receptor surface expression by a small molecule switch
Juillerat, A., Tkach, D., Busser, B. W., Temburni, S., Valton, J., Duclert, A., Poirot, L., Depil, S., & Duchateau, P. N. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0537-3 · Cited by 125
Masked Chimeric Antigen Receptor for Tumor-Specific Activation
Han, X., Bryson, P. D., Zhao, Y., Cinay, G. E., Li, S., Guo, Y., Siriwon, N., & Wang, P. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.011 · Cited by 117
Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers
Orentas, R. J., Yang, J. J., Wen, X., Wei, J. S., Mackall, C. L., & Khan, J. I. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00194 · Cited by 113
Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines
Dwyer, C. J., Knochelmann, H. M., Smith, A. S., Wyatt, M. M., Rivera, G. O. R., Arhontoulis, D. C., Bartee, E., Li, Z., Rubinstein, M. P., & Paulos, C. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00263 · Cited by 112
Wang, Y., Jiang, H., Luo, H., Sun, Y., Shi, B., Sun, R., & Li, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01691 · Cited by 112
Flexible Targeting of ErbB Dimers That Drive Tumorigenesis by Using Genetically Engineered T Cells
Davies, D. M., Foster, J., van der Stegen, S. J. C., Parente‐Pereira, A. C., Chiapero-Stanke, L., Delinasios, G. J., Burbridge, S. E., Kao, V., Liu, Z., Bosshard‐Carter, L., et al. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00493 · Cited by 110
Antagonism of IAPs Enhances CAR T-cell Efficacy
Michie, J., Beavis, P. A., Freeman, A. J., Vervoort, S. J., Ramsbottom, K. M., Narasimhan, V., Lelliott, E. J., Lalaoui, N., Ramsay, R. G., Johnstone, R. W., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0428 · Cited by 108
Xhangolli, I., Dura, B., Lee, G., Kim, D., Xiao, Y., & Fan, R. (2019) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2019.03.002 · Cited by 108
Foster, A. E., Mahendravada, A., Shinners, N. P., Chang, W.-C., Crisostomo, J., Lu, A., Khalil, M., Morschl, É., Shaw, J. L., Saha, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.014 · Cited by 107
Boroughs, A. C., Larson, R. C., Marjanovic, N. D., Gosik, K., Castaño, A. P., Porter, C. B. M., Lorrey, S., Ashenberg, O., Jerby‐Arnon, L., Hofree, M., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.07.023 · Cited by 107
Power, A., & Bell, J. C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300098 · Cited by 105
Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells
Lai, Y., Weng, J., Wei, X., Qin, L., Lai, P., Zhao, R., Jiang, Z., Li, B., Lin, S., Wang, S., et al. (2017) · Leukemia · doi:10.1038/leu.2017.249 · Cited by 105
A conformation-specific ON-switch for controlling CAR T cells with an orally available drug
Zajc, C. U., Dobersberger, M., Schaffner, I., Mlynek, G., Pühringer, D., Salzer, B., Djinović‐Carugo, K., Steinberger, P., Linhares, A. D. S., Yang, N. J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911154117 · Cited by 105
Nakazawa, T., Natsume, A., Nishimura, F., Morimoto, T., Matsuda, R., Nakamura, M., Yamada, S., Nakagawa, I., Motoyama, Y., Park, Y.-S., et al. (2020) · Cells · doi:10.3390/cells9040998 · Cited by 104
Santoro, S. P., Kim, S., Motz, G. T., Alatzoglou, D., Li, C., Irving, M. B., Powell, D. J., & Coukos, G. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0192 · Cited by 102
Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells
Iwahori, K., Kakarla, S., Velasquez, M. P., Feng, Y., Yi, Z., Gerken, C. P., Song, X., & Gottschalk, S. M. (2014) · Molecular Therapy · doi:10.1038/mt.2014.156 · Cited by 102
Self-citationMaus, M. V., Plotkin, J., Jakka, G., Stewart-Jones, G. B. E., Rivière, I., Merghoub, T., Wolchok, J. D., Renner, C., & Sadelain, M. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.23 · Cited by 99
Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products
Cornetta, K., Duffy, L., Turtle, C. J., Jensen, M., Forman, S., Binder-Scholl, G., Fry, T., Chew, A., Maloney, D. G., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.008 · Cited by 98
Collinson-Pautz, M. R., Chang, W.-C., Lu, A., Khalil, M., Crisostomo, J., Lin, P.-Y., Mahendravada, A., Shinners, N. P., Brandt, M. E., Zhang, M., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0417-9 · Cited by 98
Ma, Q., Garber, H. R., Lu, S., He, H., Tallis, E., Ding, X., Сергеева, А., Wood, M. S., Dotti, G., Salvado, B., et al. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.05.001 · Cited by 96
Allogeneic CAR T cell therapies for leukemia
Qasim, W. (2019) · American Journal of Hematology · doi:10.1002/ajh.25399 · Cited by 92
Enhancing CAR T-cell therapy through cellular imaging and radiotherapy
Minn, I., Rowe, S. P., & Pomper, M. G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30461-9 · Cited by 91
Radiation therapy and the abscopal effect: a concept comes of age
Ng, J., & Dai, T. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.01.32 · Cited by 88
Abbott, R. C., Cross, R. S., & Jenkins, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020515 · Cited by 83
Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer
Ao, X., Yang, Y. P., Li, W., Tan, Y. H., Guo, W., Ao, L., He, X., Wu, X., Xia, J., Xu, X. M., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000286 · Cited by 82
Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy
Zebley, C. C., Gottschalk, S. M., & Youngblood, B. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.008 · Cited by 80
Self-citationViral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy
Aalipour, A., Boeuf, F. L., Tang, M. Y. H., Murty, S., Simonetta, F., Lozano, A. X., Shaffer, T. M., Bell, J. C., & Gambhir, S. S. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.03.018 · Cited by 77
Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells
Hale, M. R., Lee, B., Honaker, Y., Leung, W., Grier, A. E., Jacobs, H. M., Sommer, K., Sahni, J., Jackson, S. W., Scharenberg, A. M., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.008 · Cited by 76
Human TSCM cell dynamics in vivo are compatible with long-lived immunological memory and stemness
del Amo, P. C., Lahoz-Beneytez, J., Boelen, L., Ahmed, R., Miners, K. L., Zhang, Y., Roger, L., Jones, R. E., Marraco, S. A. F., Speiser, D. E., et al. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2005523 · Cited by 76
Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy
Rivadeneira, D. B., & Delgoffe, G. M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0894 · Cited by 74
Andersch, L., Radke, J., Klaus, A., Schwiebert, S., Winkler, A., Schumann, E., Grunewald, L., Zirngibl, F., Flemmig, C., Jensen, M. C., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6131-1 · Cited by 74
Engineering of an enhanced synthetic Notch receptor by reducing ligand-independent activation
Yang, Z., Yu, Z., Cai, Y., Du, R., & Cai, L. (2020) · Communications Biology · doi:10.1038/s42003-020-0848-x · Cited by 74
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response
Li, X., Daniyan, A. F., Lopez, A. V., Purdon, T. J., & Brentjens, R. J. (2020) · Leukemia · doi:10.1038/s41375-020-0874-1 · Cited by 74
Perna, S. K., Angelis, B. D., Pagliara, D., Hasan, S. T., Zhang, L., Mahendravada, A., Heslop, H. E., Brenner, M. K., Rooney, C. M., Dotti, G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2143 · Cited by 72
Muralidharan, S., Hanley, P. J., Liu, E., Chakraborty, R., Bollard, C. M., Shpall, E. J., Rooney, C. M., Savoldo, B., Rodgers, J. R., & Dotti, G. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101585 · Cited by 72
Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells
Morita, D., Nishio, N., Saito, S., Tanaka, M., Kawashima, N., Okuno, Y., Suzuki, S., Matsuda, K., Maeda, Y., Wilson, M. H., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.003 · Cited by 72
Condomines, M., Arnason, J. E., Benjamin, R., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130518 · Cited by 71
Tang, X., Liu, F., Liu, Z., Cao, Y. L., Zhang, Z., Wang, Y., Huang, J., Fan, S., Zhao, S., Chen, Y., et al. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1137 · Cited by 71
Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells
Nguyen, P., Okeke, E., Clay, M. R., Haydar, D., Justice, J., O'Reilly, C., Pruett‐Miller, S. M., Papizan, J. B., Moore, J., Zhou, S., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.018 · Cited by 71
Self-citationThe Jak-STAT Pathway Stimulated by Interferon α or Interferon β
Horvath, C. M. (2004) · Science s STKE · doi:10.1126/stke.2602004tr10 · Cited by 69
Liu, X., Barrett, D. M., Jiang, S., Fang, C., Kalos, M. D., Grupp, S. A., June, C. H., & Zhao, Y. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.38 · Cited by 69
Bowers, J. S., Nelson, M. H., Majchrzak, K., Bailey, S. R., Rohrer, B., Kaiser, A., Atkinson, C., Gattinoni, L., & Paulos, C. M. (2017) · JCI Insight · doi:10.1172/jci.insight.90772 · Cited by 68
Rataj, F., Jacobi, S. J., Stoiber, S., Asang, F., Ogonek, J., Tokarew, N. J. A., Cadilha, B. L., van Puijenbroek, E., Heise, C., Duewell, P., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0341-1 · Cited by 60
The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas
Reiter–Brennan, C., Semmler, L., & Klein, A. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.82642 · Cited by 60
Bear, A. S., Morgan, R. A., Cornetta, K., June, C. H., Binder-Scholl, G., Dudley, M. E., Feldman, S. A., Rosenberg, S. A., Shurtleff, S. A., Rooney, C. M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.288 · Cited by 59
Schmueck‐Henneresse, M., Omer, B. A., Shum, T., Tashiro, H., Mamonkin, M., Lapteva, N., Sharma, S., Rollins, L. A., Dotti, G., Reinke, P., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601494 · Cited by 58
Internal ribosome entry site-based vectors for combined gene therapy
Renaud-Gabardos, E. (2015) · World Journal of Experimental Medicine · doi:10.5493/wjem.v5.i1.11 · Cited by 56
Xǔ, J., Wang, Y., Shi, J., Liu, J., Li, Q., & Chen, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.8946 · Cited by 56
Curioni, A., Britschgi, C., Hiltbrunner, S., Bankel, L., Gulati, P., Weder, W., Opitz, I., Lauk, O., Caviezel, C., Knuth, A. K., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz253.052 · Cited by 53
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
Alhabbab, R. Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00312 · Cited by 53
Landgraf, K. E., Williams, S. R., Steiger, D., Gebhart, D., Lok, S., Martin, D. W., Roybal, K. T., & Chan, K. (2020) · Communications Biology · doi:10.1038/s42003-020-1021-2 · Cited by 52
Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling
Nair, S., Wang, J., Tsao, S.-T., Liu, Y., Zhu, W. J., Slayton, W. B., Moreb, J. S., Dong, L., & Chang, L. (2018) · Current Gene Therapy · doi:10.2174/1566523218666181116093857 · Cited by 47
Panousis, C., Rayzman, V., Johns, T. G., Renner, C., Liu, Z., Cartwright, G. A., Lee, F.-T., Wang, D., Gan, H. K., Cao, D., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602470 · Cited by 46
Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation
Lo, A. S., Taylor, J. R., Farzaneh, F., Kemeny, D. M., Dibb, N. J., & Maher, J. F. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.09.010 · Cited by 45
Zhang, P., Zhao, S., Wu, C., Li, J., Li, Z., Wen, C., Hu, S., An, G., Meng, H., Zhang, X., et al. (2018) · Immunotherapy · doi:10.2217/imt-2018-0012 · Cited by 44
Hegde, M. G., DeRenzo, C. C., Zhang, H., Mata, M., Gerken, C. P., Shree, A., Yi, Z., Brawley, V. S., Dakhova, O., Wu, M.-F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.10508 · Cited by 42
Self-citationExcessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
Wijewarnasuriya, D., Bebernitz, C., Lopez, A. V., Rafiq, S., & Brentjens, R. J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0908 · Cited by 42
Navai, S. A., DeRenzo, C. C., Joseph, S. K., Sanber, K. S., Byrd, T. T., Zhang, H., Mata, M., Gerken, C. P., Shree, A., Mathew, P. R., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-lb-147 · Cited by 40
Self-citationLiu, K., Liu, X., Peng, Z., Sun, H., Zhang, M., Zhang, J., Liu, S., Hao, L., Lu, G., Zheng, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4362 · Cited by 26
Cited by
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Albelda, S. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 517
Co-opting signalling molecules enables logic-gated control of CAR T cells
Tousley, A. M., Rotiroti, M. C., Labanieh, L., Rysavy, L. W., Kim, W.-J., Lareau, C., Sotillo, E., Weber, E. W., Rietberg, S. P., Dalton, G. N., et al. (2023) · Nature · doi:10.1038/s41586-023-05778-2 · Cited by 321
CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities
Kankeu Fonkoua, L. A., Sirpilla, O., Sakemura, R., Siegler, E. L., & Kenderian, S. S. (2022) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2022.03.009 · Cited by 282
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Shafer, P., Kelly, L. M., & Hoyos, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835762 · Cited by 270
Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models
Dai, H., Zhu, C., Huai, Q., Xu, W., Zhu, J., Zhang, X., Zhang, X., Sun, B., Xu, H., Zheng, M., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.034 · Cited by 114
Metadata
- Authors
- Wagner, J., Wickman, E., DeRenzo, C., & Gottschalk, S.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 28
- Issue
- 11
- Pages
- 2320-2339
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W3085241535
- Cited by
- 380
- References
- 284
- FWCI
- 17.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.